King Pharmaceuticals KG Legacy Reinsurance — Commission and other acquisition expenses

Similar metrics at other companies

EGLegacy — Commission and brokerage

$41M-6.8%

AXSReinsurance — Acquisition costs

$80.49M+14.1%

SPNTReinsurance — Acquisition costs, net

$63.8M-4.9%

EGLegacy — Other underwriting expenses

$65M-36.9%

ACGLReinsurance — Acquisition expenses

$347M-16.8%

ACGLReinsurance — Acquisition expense ratio

19%-1.6pp

Other financials

Income statement

See full

Revenue$10.2M+1,112%

Net income-$7.4M-1,786%

EPS (diluted)-$0.96-586%

Balance sheet

See full

Cash & equivalents$62.2M+1,724%

Total debt$176.7M—

Total equity$121.4M+2,773%

Total assets$964.2M—

Cash flow

See full

Operating cash flow-$15.1M-1,628%

Valuation

See full

Market cap$70.42M-67.6%

Enterprise value$184.93M-50.0%

P/E1.2×—

P/S1.6×-24.3×

Profitability

See full

Net margin131.5%—

Returns & leverage

See full

Return on equity90.8%—

Debt / equity1.5×—

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:DeferredPolicyAcquisitionCostAmortizationExpense.

The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's legacy reinsurance — commission and other acquisition expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is King Pharmaceuticals's legacy reinsurance — commission and other acquisition expenses?: King Pharmaceuticals (KG) reported legacy reinsurance — commission and other acquisition expenses of $1.47M in Q1 2026.
What does legacy reinsurance — commission and other acquisition expenses mean?: Includes the costs paid to brokers or agents and other expenses directly related to acquiring new or renewal reinsurance business. Monitoring this helps evaluate the cost-efficiency of the segment's distribution strategy.